Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Biostage, Inc. (BSTG : OTC)

• Company Description    Biostage, Inc. is a biotechnology company. It is engaged in developing bioengineered organ implants based on the company's new Cellframe (TM) technology to treat life-threatening conditions of the esophagus, trachea or bronchus. Biostage Inc., formerly known as Harvard Apparatus Regenerative Technology Inc., is based in HOLLISTON, Mass. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $4.89 Daily Weekly Monthly 20 Day Moving Average: 868 shares Shares Outstanding: 13.88 (millions) Market Capitalization: $67.88 (millions) Beta: -0.95 52 Week High: $9.00 52 Week Low: $4.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.82% -20.93% 12 Week -14.21% -20.36% Year To Date -11.09% -19.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 84 October Hill Road Suite 11 - Holliston,MA 01746 USA ph: 774-233-7300 fax: 774-233-7302 jdamasio@biostage.com http://www.biostage.com

• General Corporate Information    Officers Junli He - Chief Executive Officer; Director; and Chairman Jason Jing Chen - Vice Chairman Joseph Damasio Jr. - Chief Financial Officer David Green - Director Ting Li - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09074M202 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/03/23 Share - Related Items Shares Outstanding: 13.88 Most Recent Split Date: 12.00 (0.05:1) Beta: -0.95 Market Capitalization: $67.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -20.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/23 - - 12/31/22 - - 09/30/22 - - ROA 03/31/23 - -174.43 12/31/22 - -157.80 09/30/22 - -281.32 Current Ratio 03/31/23 - 2.73 12/31/22 - 1.17 09/30/22 - 2.21 Quick Ratio 03/31/23 - 2.73 12/31/22 - 1.17 09/30/22 - 2.21 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Book Value 03/31/23 - -0.08 12/31/22 - -0.26 09/30/22 - -0.16 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Capital 03/31/23 - - 12/31/22 - - 09/30/22 - -

Powered by Zacks Investment Research ©